The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Wyn, you blame avacta for not selling.
What would you pref? They grease the palms of the MP's, cut dodgy back handers to back benchers to sell a few million tests? To then be dragged across the coals by Good Law Project et al? This is what you are advocating for ?
Bloody blessing in disguise not being involved in that racket and anyone who thinks different needs to do more DD into COVID contracts.
Anyways, most the companies who got contracts have been wound up now. Poof! the money has disappeared!
Always a little concerning as we sit at £1 and most M&A 50-100% premium. (some slightly higher) This would mean we wouldn't even achieve an ATH from a Buyout following similar leads.
Looking at Chinook Therapeutics, lows of $5 around start of 2020 - Buy out $40 in 2023, a healthy return.
We were £1.80 only a few months ago and what many might have thought as our new support.
We will have a base SP around £1-£2 if we follow the same method, and I would like to see that reflect us like we were Chinook Therapeuticsat at $5.
P1a/b should give us that natural lift towards a similar end point.
Wyn, is it really that hard to understand?
Each cohort has the potential to find an MTD and progress no longer.
Avacta are a victim of their own drugs success which has lead to increased timelines. AS can only guess at timeframes, at the moment, based on around 60-80 days for each cohort. P1a could finish, 60 days after the first ever patient dosed, if no MTD found, then we go again, and again and again until found.
Not a hard concept to grasp but you labour on about it. We could have been well into P1b if the drug wasn’t as good, thankfully it’s turning into something really bloody special.
Wyn, hard to have serious conversations on this board most of the time.
And im finding more and more just to take what the company says as what is going to happen, rather than trying to read between the lines and hypothesis an explanation of the actions. They said further M&A tho and M.M said as much in tweets but nobody seems to want to believe it.
Would i preferred all cash going towards Tx? Sure...
They might still have enough cash for P1B... and they could have explained the cash position more clearly for Tx following this as it just leaves more speculation and interpretation.
Progress on Dx at this point in the trial just muddles the waters for investors, we have a split company for a small cap AIM listed company with both divisions competing for capital expenditure, the Dx direction does fit in to an overall company strategy and I think they are done now on Dx. Now to establish the pathway for Tx and drive that forward to cash generating position... first being a potential license which could enable us to progress AVA6K and 3996 as far as possible.
Still under the opinion that there will be a Tx sell off.. progression on Dx does look more now to a split sale, and adds further complications.
Who knows, establish Dx enough to make it a sweetener to $10bn Full TO deal, and you wont get any complaints of strategy or decisions from PI's.
We wait Tx progress now for the end or next Cohort and AGM.
Well I guess some of my fears that the M&A Dx was not finished, and the “fully funded line” was not a guarantee if they persist with Dx activities as stated in the previous RNS.
Although I got some particular stick for raising this, this certainly will be interesting to see how the strategy plays out now. Am I happy they continue with Dx? I’m really not sure when the golden goose of Tx needs cash.
We are now back to guessing that there MUST be a deal in the outwings to cover Tx, but as we all seem to think Avacta are multi layered, it’s usually just as it seems.
We are not the CEO, and as said before we really don’t have all the facts to establish the future direction with funding options, but it does show some brass balls as we near the end of P1a.
We wait.
Always find censoring poor form.
Better speech defeats poor speech.
Much better to defeat failed reasoning with sound reasoning.
For a few it’s just easier resorting to name calling because sometimes this board is just unreasonable, undebatable, uncompromising and at times bloody frustrating.
But here we are, nature of the Avacta BB unfortunately.
We all wait.
PL, did AS not say himself that “6K is being dosed at therapeutic levels in one of the presentations?
Which is likely backed up by biopsies and other data?
Safety? Tick
Therapeutically relevant? Tick
Cleaving? Tick
In my opinion, it’s all but proven and risk off.
Was Avacta always about STS?
https://avacta.com/about/ip/
24 Oct 2022
https://www.trademarkelite.com/uk/trademark/trademark-detail/UK00002602241/Sarcoma-UK
Previous expired on EXPIRY DATE Nov 23, 2021
Credits to Mcfly on Twitter.
What could a precision license value be?
https://www.takeda.com/newsroom/newsreleases/2023/takeda-completes-acquisition-of-nimbus-therapeutics-tyk2-program-subsidiary/
Under the terms of the agreement and following the closing of the transaction, Takeda will pay Nimbus approximately 4 billion USD upfront, after adjusting items including closing indebtedness and closing account payable of Lakshmi. Takeda will also make two milestone payments to Nimbus of 1 billion USD each upon achieving annual net sales of 4 billion USD and 5 billion USD of products developed from the TAK-279 program.
Https://www.biopharmadive.com/news/biotech-deals-immunology-acquisitions-merck-prometheus/647802/#:~:text=On%20Sunday%2C%20Merck%20%26%20Co.%20disclosed%20plans%20to,regulates%20the%20immune%20system%2C%20for%20almost%20%2411%20billion.
https://pharmaphorum.com/news/merck-fires-108bn-prometheus-takeover-bid
Interesting that lots of Biotechs in Trials have significantly higher MCAP than us.
Big Bio are willing to spend the cash on key developments.
Patent cliffs across Big bio is an obvious concern to bottom line revenues.
Big Bio have such firepower, $10bn all cash offer isnt a problem.
PL, finally a bit of reasoning and understanding of the point I’m making. I’m not advocating like wyn is they will buy ABDX, they could buy anything Dx related and have said they won’t in that area.
Wouldn’t it have been good if they said “no further M&A activity planned”
Part of my whole point really of understanding what’s in the RNS and in parts what M.M was saying.
Quote from my post at 1201
Yeah Thompi, totally get it.
Its just sometimes a place of frustration for me when members just blindly say - Fully funded. Thats what the company said, correct but they have also said other things to the contrary.
Yes, exactly. Totally missing what I’m saying. Think some concepts are too big for some of you to understand.
Better saying I’m a paid deramper than actually engage with the subject.
There’s no conversation with you lot.
You take things out of context or just ignore what’s been actually said.
If Avacta come out and bought another company and spent another huge chunk of the HC bond you would be praising it as amazing.
Go check back what Myles McNulty was saying regarding further M&A for Dx.
You ignore everything else and stick your head in the sand.
We are fully funded if we don’t progress with further M&A.
If we spend it then we aren’t fully funded.
What so hard to get your thick skulls around that idea?
I give up.